Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | PPID | Q08752 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30700389 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MAPTPOLBTDP1RAB9A | |
| Hydrochloric Acid SCHEMBL5434602 | 0.99 | ALDH1A1 (0.55) | ALDH1A1MAPTPOLBTDP1RAB9A | |
| SCHEMBL2593071 | 0.90 | ALDH1A1 (0.53) | ALDH1A1MAPTPOLBTDP1RAB9A | |
| SCHEMBL22612137 | 0.86 | CHRM2 (0.51) | ALDH1A1MAPTPOLBTDP1RAB9A | |
| Hydrochloric Acid SCHEMBL16585744 | 0.85 | SMN1; SMN2 (0.54) | ALDH1A1MAPTPOLBTDP1RAB9A | |
| SCHEMBL31215234 | 0.85 | PPID (0.64) | ALDH1A1RAB9ASMN1; SMN2ALOX15L3MBTL1 | |
| Hydrochloric Acid SCHEMBL8615293 | 0.85 | ALDH1A1 (0.51) | ALDH1A1MAPTTDP1RAB9ALMNA | |
| SCHEMBL2039737 | 0.85 | PPID (0.64) | ALDH1A1RAB9ASMN1; SMN2ALOX15L3MBTL1 | |
| SCHEMBL22747356 | 0.83 | ALDH1A1 (0.52) | ALDH1A1MAPTPOLBTDP1RAB9A | |
| SCHEMBL7712013 | 0.81 | MAPT (0.60) | ALDH1A1MAPTPOLBTDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1180991-B1 | GAMBOGIC ACID DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2010-05-19 | — | — | EP | claimed |
| EP-1180991-A4 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2005-10-12 | — | — | EP | claimed |
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2003-04-24 | — | — | US | claimed |
| US-6462041-B1 | ACTIVATORS OF CASPASE CASCADE; TREATING, PREVENTING OR AMELIORATING NEOPLASIA AND CANCER | CYTOVIA, INC. | 2002-10-08 | — | — | US | claimed |
| EP-1180991-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000044216-A1 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| CN-106029104-A | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | 奥斯陆大学 | 2016-10-12 | — | — | CN | disclosed |
| CN-102844320-A | Heterocyclic compounds | TAKEDA PHARMACEUTICAL | 2012-12-26 | — | — | CN | disclosed |
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-1180991-B1 | GAMBOGIC ACID DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090259054-A1 | Methods and Compositions for the Treatment of Angiogenesis and Macular Degeneration | THE TEXAS A&M UNIVERSITY SYSTEM | 2009-10-15 | — | — | US | disclosed |
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| EP-0457195-B1 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CASP5, CASP3, CASP7 | ALDH1A1 2828/4885MAPT 4809/4885POLB 2641/4885 |
| US-20090259054-A1 | Methods and Compositions for the Treatment of Angiogenesis and Macular Degeneration | PDE6D, PDE6H, VEGFA | ALDH1A1 574/4885MAPT 3618/4885POLB 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.